Human subjects
Peripheral blood and bone marrow samples were obtained from AML patients after informed consent had been obtained in accordance with The University of Texas MD Anderson Cancer Center (Houston, Texas) institutional review board regulations (Supplementary  Table S1 ). Mononuclear cells in primary samples were separated using a Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich). Isolated cells were cultured in RPMI 1640 medium containing 10% FBS, 1 mmol/L L-glutamine and 50 μg/mL penicillin/ streptomycin. Normal human adult bone marrow mesenchymal stromal cells (MSC) were isolated from bone marrow aspirates from the iliac crest of healthy volunteers after informed consent according to institutional guidelines of the Declaration of Helsinki. MSC isolation, expansion and purification were performed according to a previously described protocol (1); enriched MSC were maintained in α-minimum essential medium (α-MEM; Thermo Fisher Scientific) supplemented with 20% FBS, 1 mmol/L L-glutamine and 50 μg/mL penicillin/ streptomycin.
Co-culture of leukemic cells and MSC
MSCs were plated and cultured in α-MEM medium (20% FBS, 1 mmol/L L-glutamine and 50 μg/ mL penicillin/streptomycin) overnight. After removal of the culture medium, leukemic cells were seeded on top of MSC at a ratio of 1:100 (MSC: leukemic cells) and co-cultured in RPMI-1640 medium (10% FBS, 1 mmol/L L-glutamine and 50 μg/mL penicillin/ streptomycin) for 3 hours, after which co-cultures were exposed to single agents or their combinations at the indicated concentrations in normoxia or hypoxia for 48 hours.
To determine the treatment effect on the co-cultured leukemic cells in normoixa or hypoxia conditions, AML cells were harvested and separated from MSC according to a previously described protocol (14). Cell viability was measured by Cell Titer-Glo® Luminescent viability assay. Apoptosis induction on AML cells (CD45+/CD34+) was analyzed by flow cytometry (CD45, BD Pharmingen). Specific apoptosis was calculated as described in the main text.
Western blot analysis
Antibodies against human p-AKT (Ser473) (phosphorylated AKT(Ser473)), p-AKT(Thr308), p-GSKα/ β(Ser21/9), p-S6K(Ser240/244), p-PRAS40(Ser246), p-4EBPGSK b1(Thr37/46), AKT, S6K, 4EBP1, PRAS40, and GSKβ were purchased from Cell Signaling Technology. GAPDH, used as a loading control, was purchased from Abcam.
CyTOF assay
Cryopreserved peripheral blood mononuclear cells were thawed and rested in 20% FBS RPMI medium that contained heparin (0.1 mg/ml, Alfa Aesar), MgSO 4 (100 mM) and DNase (10 units/ml) (both from Thermo Fisher Scientific) for 1 hour before use. Freshly sorted cells from mouse bone marrow or spleen were rested in 20% FBS RPMI medium for 2 hours before use. Cells with 95% or higher viability were treated with 0.1 μM MLN0128 for 60 minutes, stimulated with stem cell factor (SCF; 100 ng/mL), or GM-CSF (100 U/mL), or IL-6 (100 ng/ mL) for 5 minutes, and fixed with paraformaldehyde at a final concentration of 1.6% at room temperature for 10 minutes. Cells were washed three times with washing buffer (phosphate-buffered saline [PBS], 0.5% bovine serum albumin [BSA] , and 0.02% sodium azide) and resuspended in staining buffer (0.5% BSA-PBS) at a concentration of 1 million cells/35 μl. Antibody mix (15 μl) against cell surface molecules (Supplementary Table  S3 ) was added to the resuspended cells to the final staining volume of 50 μL. Cells were incubated for 30 minutes at room temperature and washed twice with washing buffer. The pellet was then resuspended in 300 μl of 1.6% PFA-PBS, incubated for 10 minutes at room temperature, and spun down at 1000 g for 3 minutes at 4°C. Cells were permeabilized by 1 ml of cold 70% methanol for 10 minutes on ice, washed three times with washing buffer, and resuspended in staining buffer (1 million cells/35 μl) before 15 μl of antibody mix against intracellular molecules (Supplementary Table S3 ) was added. Cells were stained for 30 minutes at room temperature. Stained cells were washed three times with washing buffer and incubated with 0.5 ml of 1.6% PFA-PBS containing 250 nM Ir-intercalator for 20 minutes at room temperature or overnight at 4°C. Cells were then washed two times with washing buffer and filtered with distilled water through blue-capped cell strainer tubes (Thermo Fisher Scientific) to remove clumps. Filtered cells were counted and spun down, leaving cell pellets (1×10 6 ) in a residual volume of distilled water (50 μl). Eu151/153 beads were added to cells before the cells were transferred to a 96-deep well plate. An autosampler device (Fluidigm Corporation) was used to apply the sample to the CyTOF instrument. Heatmap of surface markers (black to yellow) was scaled on the baseline expression intensities of both spleen and bone marrow samples. Heatmap of intracellular molecules (green to red) was scaled on the expression intensities of baseline, inhibition (MLN0128, "I"), stimulation (stimuli, "S") and inhibition followed by simulation ("I and S") of both spleen and bone marrow samples. Figure S5 : Anti-leukemic efficacy of MLN0128 and rapamycin in primary AML. Primary AML samples were treated with MLN0128 or rapamycin at the indicated concentration for 72 hours. Apoptosis induction in bulk (#4) and progenitor CD34+ cells (#3 and #5) was detected by flow cytometry. Specific apoptosis was calculated as described in the methods section. CalcuSyn software was used to determine the IC 50 and generate the dose-effect curve of MLN0128 and rapamycin for each sample. Clinical information on primary AML is included in the Supplementary Table S1, combination apoptosis set B. 
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